The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients
Luis Ayerbe, Carlos Risco-Risco, Salma Ayis
Internal and Emergency Medicine, doi:10.1007/s11739-020-02505-x
This study investigates the association between the treatment with hydroxychloroquine and mortality in patients admitted with COVID-19. Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with COVID-19, admitted in 17 hospitals in Spain between the 1st of March and the 20th of April 2020 were used. The following variables were extracted for this study: age, gender, temperature, and saturation of oxygen on admission, treatment with hydroxychloroquine, azithromycin, heparin, steroids, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir, together with data on mortality. Multivariable logistic regression models were used to investigate the associations. At the time of collecting the data, 301 patients had died, 1449 had been discharged home from the hospitals, 240 were still admitted, and 85 had been transferred to hospitals not included in the study. Median follow-up time was 8 (IQR 5-12) days. Hydroxychloroquine had been used in 1857 patients. Hydroxychloroquine was associated with lower mortality when the model was adjusted for age and gender, with OR (95% CI): 0.44 (0.29-0.67). This association remained significant when saturation of oxygen < 90% and temperature > 37 °C were added to de model with OR 0.45 (0.30-0.68) p < 0.001, and also when all the other drugs, and time of admission, were included as covariates. The association between hydroxychloroquine and lower mortality observed in this study can be acknowledged by clinicians in hospitals and in the community. Randomized-controlled trials to assess the causal effects of hydroxychloroquine in different therapeutic regimes are required.
Compliance with ethical standards Conflict of interests The author(s) declare that they have no conflict of interest.
Ethical approval The ethics committee of HM Hospitales approved this study. Data were anonymized before the authors could access it. No results that may make patients identifiable are reported.
Statements on human and animal rights The study was conducted in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
Informed consent This study was conducted on already available clincal data and informed consent was not required. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. Publisher's Note Springer Nature..
References
Arshad, Kilgore, Chaudhry, Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis,
doi:10.1016/j.ijid.2020.06.099Biot, Daher, Chavain, Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities, J Med Chem
Boulware, Pullen, Bangdiwala, A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19, N Engl J Med
Cavalcanti, Zampieri, Rosa, Hydroxychloroquine with or without azithromycin in mild-to-moderate COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2019014Chen, Zhang, Fu, Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study,
doi:10.1101/2020.06.19.20136093v1Chorin, Wadhwani, Magnani, QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin, Heart Rhythm,
doi:10.1016/j.hrthm.2020.05.014Fantini, Scala, Chahinian, Yahi, Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105960Garcia-Cremades, Solans, Hughes, Optimizing hydroxychloroquine dosing for patients with COVID-19: an integrative modeling approach for effective drug repurposing, Clin Pharmacol Ther,
doi:10.1002/cpt.1856Gautret, Lagier, Parola, Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study, Travel Med Infect Dis,
doi:10.1016/j.ijantimicag.2020.105949Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Geleris, Sun, Platt, Observational study of hydroxychloroquine in hospitalized patients with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2012410Gilead, An Open Letter from Daniel O'Day
Guastalegname, Vallone, Could chloroquine /hydroxychloroquine be harmful in Coronavirus Disease 2019 (COVID-19) treatment?, Clin Infect Dis,
doi:10.1093/cid/ciaa321Guérin, Lévy, Thomaset, Azithromycin and hydroxychloroquine accelerate recovery of outpatients with mild/ moderate COVID-19, Asian J Med Health
Hm Hospitales, None
Lagier, Million, Gautret, Outcomes of 3737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis, Travel Med Infect Dis,
doi:10.1016/j.tmaid.2020.101791Lancet, COVID-19: learning from experience, Lancet
Leung, Wu, Liu, Leunget, First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment, Lancet
Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov,
doi:10.1038/s41421-020-0156-0Mahévas, Tran, Roumier, Clinical efficacy of hydroxychloroquine in patients with COVID-19 pneumonia who require oxygen: observational comparative study using routine care data, BMJ
Membrillo, Ramírez-Olivencia, Estébanez, Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study
Million, Gautret, Colson, Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: comparative meta-analysis between the Big data and the real world, New Microbes New Infect,
doi:10.1016/j.nmni.2020.100709Nice-Bnf, Hydroxychloroquine Sulfate
Patel, Paranjpe, Kathiresan, Rivas, Khera, Race, socioeconomic deprivation, and hospitalization for COVID-19 in English participants of a national biobank, Int J Equity Health,
doi:10.1186/s12939-020-01227-yRaoult, Million, Gautret, Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an 2 Open-Label Non-Randomized Clinical Trial: Response to David Spencer
Recovery, No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
Rosenberg, Dufort, Udo, Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State, JAMA,
doi:10.1001/jama.2020.8630Sbidian, Josse, Lemaitre, Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4642 in-patients in France,
doi:10.1101/2020.06.16.20132597v1Scholz, Derwand, Zelenko, COVID-19 Outpatients-early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study
Skipper, Pastick, Engen, Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial, Ann Intern Med,
doi:10.7326/M20-4207Tang, Cao, Han, Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ,
doi:10.1136/bmj.m1849Walker, Whittaker, Watson, The global impact of COVID-19 and strategies for mitigation and suppression
Who, )-and-the-virus -that-cause s-it
Who, Coronavirus disease (COVID-19) Pandemic
Who, Solidarity" clinical trial for COVID-19 treatments
Who, WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19
Wise, COVID-19: risk of second wave is very real, say researchers, BMJ
Worldometer, COVID-19 CORONAVIRUS PANDEMIC
Wu, Leung, Bushman, Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China Nat Med
Yu, Li, Chen, Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19, Sci China Life Sci,
doi:10.1007/s11427-020-1732-2
